Ceroid lipofuscinosis type 2 disease: Effective presymptomatic therapy-Oldest case of a presymptomatic enzyme therapy. [PDF]
Breuillard D +11 more
europepmc +1 more source
Proximity labeling reveals non-catalytic interactions between DPP9 and ubiquitin signaling complexes. [PDF]
Wirtgen VE +10 more
europepmc +1 more source
The non-structural protein of SFTSV activates NLRP1 and CARD8 inflammasome through disrupting the DPP9-mediated ternary complex. [PDF]
Liu PP +5 more
europepmc +1 more source
Role of IPF genetic risk loci in post-COVID-19 lung abnormalities: a cohort study. [PDF]
Marinescu DC +9 more
europepmc +1 more source
The multifunctional regulatory post-proline protease dipeptidyl peptidase 9 and its inhibitors: new opportunities for therapeutics. [PDF]
Nguyen JMH +3 more
europepmc +1 more source
Intraventricular Cerliponase Alfa Treatment in a Patient with Advanced Neuronal Ceroid Lipofuscinosis Type 2. [PDF]
Nakashima S +9 more
europepmc +1 more source
Identification and functional characterization of regulatory variants in DPP9 associated with COVID-19 severity. [PDF]
Farah G +10 more
europepmc +1 more source
The Caenorhabditis elegans DPF-3 and Human DPP4 Have Tripeptidyl Peptidase Activity [PDF]
The dipeptidyl peptidase IV (DPPIV) family comprises serine proteases classically defined by their ability to remove dipeptides from the N‐termini of substrates, a feature that gave the family its name. Here, we report the discovery of a previously unrecognized tripeptidyl peptidase activity in DPPIV family members from two different species.
Aditya Trivedi, Rajani Kanth Gudipati
exaly +3 more sources
Related searches:

